Effect of clofibrate on vascular reactivity in a model of high blood pressure secondary to aortic coarctation
- PMID: 21098870
- DOI: 10.1016/s1734-1140(10)70347-9
Effect of clofibrate on vascular reactivity in a model of high blood pressure secondary to aortic coarctation
Abstract
The aims of this study were to identify the effect of clofibrate administration in the development of high blood pressure secondary to aortic coarctation (AoCo) and to assess its effect on vascular reactivity. Three experimental groups of rats were used: sham-operated, aortic coarctated vehicle-treated (AoCo-V), and aortic coarctated clofibrate-treated (AoCo-C100). The rats were treated for seven days. Blood pressure was measured, and the vascular response to angiotensin II (AngII), norepinephrine (NE), and acetylcholine (ACh) were evaluated in aortic rings. The activity and expression of endothelial nitric oxide synthase (eNOS) was also evaluated. The major findings of this study include the following: AoCo induced a rise in blood pressure, and this effect was attenuated by clofibrate. The vascular response to AngII was higher in aortic rings from the AoCo-V group compared to the Sham-V or AoCo-C100 groups. ACh-elicited vasorelaxation was lower in the arteries of AoCo-V rats than Sham-V or AoCo-C100, while it was comparable between the Sham-V and AoCo-C100 groups. In every case, vasorelaxation was dependent on NO. However, the ACh-induced release of NO as well as NOS activity and expression were reduced in the arteries of AoCo-V rats. Clofibrate maintained normal NOS activity and increased eNOS expression. In conclusion, clofibrate administration attenuated the AoCo-induced rise in blood pressure by a mechanism that involves the participation of the NO system at both the NO synthesis and the eNOS protein expression levels. These events improved endothelial function, preserved normal vascular responses to both vasorelaxants and vasoconstrictors, and led to better blood pressure control.
Similar articles
-
Endothelial nitric oxide synthase impairment is restored by clofibrate treatment in an animal model of hypertension.Eur J Pharmacol. 2012 Jun 15;685(1-3):108-15. doi: 10.1016/j.ejphar.2012.04.006. Epub 2012 Apr 20. Eur J Pharmacol. 2012. PMID: 22542661
-
PPARalpha stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner.Eur J Pharmacol. 2010 Feb 10;627(1-3):185-93. doi: 10.1016/j.ejphar.2009.10.039. Epub 2009 Oct 24. Eur J Pharmacol. 2010. PMID: 19857485
-
Peroxisome proliferator-activated receptor-α stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle.Pharmacol Rep. 2016 Aug;68(4):692-702. doi: 10.1016/j.pharep.2016.03.002. Epub 2016 Mar 21. Pharmacol Rep. 2016. PMID: 27110876
-
Endothelial dysfunction in rat adjuvant-induced arthritis: up-regulation of the vascular arginase pathway.Arthritis Rheum. 2011 Aug;63(8):2309-17. doi: 10.1002/art.30391. Arthritis Rheum. 2011. PMID: 21484767
-
Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats.Vascul Pharmacol. 2006 May;44(5):290-8. doi: 10.1016/j.vph.2005.12.005. Epub 2006 Mar 15. Vascul Pharmacol. 2006. PMID: 16542882
Cited by
-
Congestive heart failure: experimental model.Front Pediatr. 2013 Oct 28;1:33. doi: 10.3389/fped.2013.00033. eCollection 2013. Front Pediatr. 2013. PMID: 24400279 Free PMC article.
-
Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation.PPAR Res. 2019 Feb 3;2019:1371758. doi: 10.1155/2019/1371758. eCollection 2019. PPAR Res. 2019. PMID: 30863432 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical